<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">helmholtzeyeinstitute</journal-id><journal-title-group><journal-title xml:lang="ru">Российский офтальмологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Ophthalmological Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0076</issn><issn pub-type="epub">2587-5760</issn><publisher><publisher-name>Real time Publishers</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21516/2072-0076-2025-18-2-160-167</article-id><article-id custom-type="elpub" pub-id-type="custom">helmholtzeyeinstitute-1780</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Эффективность и безопасность ципрофлоксацина, мази глазной и капель для глаз, 0,3 %, в современной терапии инфекционно-воспалительных заболеваний глаз. Обзор литературы</article-title><trans-title-group xml:lang="en"><trans-title>Efficacy and safety of ciprofloxacin, eye ointment and eye drops, 0.3 %, in modern therapy of infectious and inflammatory eye diseases. A review</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-5112-5321</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Трубилин</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Trubilin</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Трубилин Александр Владимирович — канд. мед. наук, доцент кафедры офтальмологии.</p><p>Волоколамское ш., д. 91, Москва, 125371</p></bio><bio xml:lang="en"><p>Aleksandr V. Trubilin — Cand. of Med. Sci., associate professor of chair of ophthalmology.</p><p>91, Volokolamskoye highway, Moscow, 125371</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8551-0661</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полунина</surname><given-names>Е. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Polunina</surname><given-names>E. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Полунина Елизавета Геннадьевна — д-р мед. наук, профессор, профессор кафедры офтальмологии.</p><p>Волоколамское ш., д. 91, Москва, 125371</p></bio><bio xml:lang="en"><p>Elizaveta G. Polunina – Dr. of Med. Sci., professor, professor of chair of ophthalmology.</p><p>91, Volokolamskoye highway, Moscow, 125371</p></bio><email xlink:type="simple">lpolunina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8948-5029</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Серебрянникова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Serebryannikova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Серебрянникова Елена Александровна — канд. фарм. наук, медицинский писатель.</p><p>ул. Парниковая, д. 8, Екатеринбург, 620135</p></bio><bio xml:lang="en"><p>Elena A. Serebryannikova — Cand. of Pharm. Sci., medical writer.</p><p>8, Parnikovaya St., Ekaterinburg, 620135</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0474-6638</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иксанова</surname><given-names>А. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Iksanova</surname><given-names>A. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Иксанова Альфия Габдулахатовна — канд. биол. наук, старший научный сотрудник.</p><p>ул. Кремлевская, д. 18, Казань, 420008</p></bio><bio xml:lang="en"><p>Alfiya G. Iksanova –– Cand. of Biol. Sci., senior researcher, scientific and educational center of pharmaceutics.</p><p>18, Kremlevskaya St., Kazan, 420008</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-0173-3817</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Устинова</surname><given-names>Т. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Ustinova</surname><given-names>T. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Устинова Татьяна Дмитриевна — бренд-менеджер медицинского отдела.</p><p>ул. Беломорская, д. 260, Казань, 420091</p></bio><bio xml:lang="en"><p>Tatyana D. Ustinova — brand manager, medical department.</p><p>260, Belomorskaya St., Kazan, 420091</p></bio><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Академия постдипломного образования ФГБУ ФНКЦ ФМБА России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Academy of postgraduate education of FMBA of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>OOO «Сайнсфайлз»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>OOO “Sciencefiles”</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Научно-образовательный центр фармацевтики ФГАОУ ВО «Казанский (Приволжский) федеральный университет»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kazan (Volga Region) Federal University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>АO «Татхимфармпрепараты»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>AO “Tatkhimfarmpreparaty”</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>14</day><month>06</month><year>2025</year></pub-date><volume>18</volume><issue>2</issue><fpage>160</fpage><lpage>167</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Трубилин А.В., Полунина Е.Г., Серебрянникова Е.А., Иксанова А.Г., Устинова Т.Д., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Трубилин А.В., Полунина Е.Г., Серебрянникова Е.А., Иксанова А.Г., Устинова Т.Д.</copyright-holder><copyright-holder xml:lang="en">Trubilin A.V., Polunina E.G., Serebryannikova E.A., Iksanova A.G., Ustinova T.D.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://roj.igb.ru/jour/article/view/1780">https://roj.igb.ru/jour/article/view/1780</self-uri><abstract><p>Бактериальный конъюнктивит является основной причиной обращений пациентов к офтальмологам, причем заболеваемость высока как среди детей, так и среди взрослых. В действующей редакции Клинических рекомендаций раздела «Конъюнктивиты», одобренной Научно-практическим советом Минздрава РФ, в качестве этиотропной терапии для лечения инфекционного конъюнктивита (бактериального, хламидийного) или при подозрении/профилактике вторичной бактериальной инфекции при конъюнктивите другой этиологии с антибактериальной целью рекомендуются антибактериальные и антисептические средства. Антибактериальные средства в лекарственной форме капель для глаз представлены следующими международными непатентованными наименованиями (МНН): офлоксацин, ципрофлоксацин, левофлоксацин, моксифлоксацин, нетилмицин, тобрамицин, хлорамфеникол, в лекарственной форме глазных мазей: МНН тетрациклин, эритромицин, тетрациклин + хлорамфеникол. Из антисептических средств представлены капли для глаз с МНН пиклоксидин и бензилдиметил-миристоиламино-пропиламмоний. В настоящем обзоре систематизированы данные, посвященные сравнительной эффективности и безопасности глазных капель и мази ципрофлоксацина, а также оценке их клинической значимости в лечении бактериальных инфекций глаз.</p></abstract><trans-abstract xml:lang="en"><p>Bacterial conjunctivitis is the main reason for patients to visit ophthalmologists, and the incidence is high among both children and adults. In the current version of the Clinical Guidelines for the section “Conjunctivitis”, approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation, antibacterial and antiseptic agents are recommended as etiotropic therapy for the treatment of infectious conjunctivitis (bacterial, chlamydial) or in case of suspicion/prevention of secondary bacterial infection in conjunctivitis of other etiologies with antibacterial purposes. Antibacterial agents in the dosage form of eye drops are represented by the following International Nonproprietary Names (INN): ofloxacin, ciprofloxacin, levofloxacin, moxifloxacin, netilmicin, tobramycin, chloramphenicol, in the dosage form of eye ointments: INN tetracycline, erythromycin, tetracycline + chloramphenicol. Of the antiseptic agents, eye drops are presented with the INN picloxidine and benzyldimethyl-myristoylamino-propylammonium. Thе review presents the comparative efficacy and safety of ciprofloxacin eye drops and ointment, as well as on the assessment of their clinical significance in the treatment of bacterial eye infections.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>блефароконъюнктивит</kwd><kwd>блефарит</kwd><kwd>конъюнктивит</kwd><kwd>ячмень</kwd><kwd>фторхинолоны</kwd><kwd>ципрофлоксацин</kwd><kwd>капли для глаз</kwd><kwd>глазная мазь</kwd></kwd-group><kwd-group xml:lang="en"><kwd>blepharoconjunctivitis</kwd><kwd>blepharitis</kwd><kwd>conjunctivitis</kwd><kwd>barley</kwd><kwd>fluoroquinolones</kwd><kwd>ciprofloxacin</kwd><kwd>eye drops</kwd><kwd>eye ointment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Клинические рекомендации «Конъюнктивиты». Available at: https://cr.minzdrav.gov.ru/schema/629_2</mixed-citation><mixed-citation xml:lang="en">Clinical guidelines “Conjunctivitis” (In Russ.) Available at: https://cr.minzdrav.gov.ru/schema/629_2</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Hobden JA, O’Callaghan RJ, Insler MS, Hill JM. Ciprofloxacin ointment versus ciprofloxacin drops for therapy of experimental Pseudomonas keratitis. Cornea. 1993 Mar; 12 (2): 138–41. doi: 10.1097/00003226-199303000-00008</mixed-citation><mixed-citation xml:lang="en">Hobden JA, O’Callaghan RJ, Insler MS, Hill JM. Ciprofloxacin ointment versus ciprofloxacin drops for therapy of experimental Pseudomonas keratitis. Cornea. 1993 Mar; 12 (2): 138–41. doi: 10.1097/00003226-199303000-00008</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lin A, Rhee MK, Akpek EK, et al. American Academy of Ophthalmology preferred practice pattern cornea and external disease panel. Bacterial Keratitis Preferred Practice Pattern®. Ophthalmology. 2019 Jan; 126 (1): P1–P55.</mixed-citation><mixed-citation xml:lang="en">Lin A, Rhee MK, Akpek EK, et al. American Academy of Ophthalmology preferred practice pattern cornea and external disease panel. Bacterial Keratitis Preferred Practice Pattern®. Ophthalmology. 2019 Jan; 126 (1): P1–P55.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Бабушкин А.Э., Шевчук Н.Е. Бактериальные конъюнктивиты (обзор литературы). Точка Зрения Восток — Запад. 2021; 3: 87–90. https://doi.org/10.25276/2410-1257-2021-3-87-90</mixed-citation><mixed-citation xml:lang="en">Babushkin A.E., Shrvchuk N.E. Bacterial conjunctivitis (literature review). Point of View. East–West. 2021; 3: 87–90 (In Russ.). https://doi.org/10.25276/2410-1257-2021-3-87-90</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hyndiuk RA, Skorich DN, Davis SD, et al. Fortified antibiotic ointment in bacterial keratitis. Am J Ophthalmol. 1988 Mar 15; 105 (3): 239–43. doi: 10.1016/0002-9394(88)90002-5</mixed-citation><mixed-citation xml:lang="en">Hyndiuk RA, Skorich DN, Davis SD, et al. Fortified antibiotic ointment in bacterial keratitis. Am J Ophthalmol. 1988 Mar 15; 105 (3): 239–43. doi: 10.1016/0002-9394(88)90002-5</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Lomholt JA, Møller JK, Eh lers N. Prolonged persistence on the ocular surface of fortified gentamicin ointment as compared to fortified gentamicin eye drops. Acta Ophthalmol. Scand. 2000; 78 (1): 34–6. doi: 10.1034/j.1600-0420.2000.078001034.x</mixed-citation><mixed-citation xml:lang="en">Lomholt JA, Møller JK, Eh lers N. Prolonged persistence on the ocular surface of fortified gentamicin ointment as compared to fortified gentamicin eye drops. Acta Ophthalmol. Scand. 2000; 78 (1): 34–6. doi: 10.1034/j.1600-0420.2000.078001034.x</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hashemi K, Chuang AZ, Schweitzer C, Lanier JD. Comparison of antibiotic drops placed in the conjun ctival cul-de-sac to antibiotic ointment applied to the lid margin in reduction of bacterial colonization on the lid margin. Cornea. 2000 Jul; 19 (4): 459–63. doi: 10.1097/00003226-200007000-00010</mixed-citation><mixed-citation xml:lang="en">Hashemi K, Chuang AZ, Schweitzer C, Lanier JD. Comparison of antibiotic drops placed in the conjun ctival cul-de-sac to antibiotic ointment applied to the lid margin in reduction of bacterial colonization on the lid margin. Cornea. 2000 Jul; 19 (4): 459–63. doi: 10.1097/00003226-200007000-00010</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Li X, Liu L, Deng Y, et al. Pharmacokinetics and bioequivalence of a generic empagliflozin tablet versus a brand-named product and the food effects in healthy Chinese subjects. Drug Dev Ind Pharm. 2020 Sep; 46 (9): 1487–94. doi: 10.1080/03639045.2020.1810263</mixed-citation><mixed-citation xml:lang="en">Li X, Liu L, Deng Y, et al. Pharmacokinetics and bioequivalence of a generic empagliflozin tablet versus a brand-named product and the food effects in healthy Chinese subjects. Drug Dev Ind Pharm. 2020 Sep; 46 (9): 1487–94. doi: 10.1080/03639045.2020.1810263</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou J.S. Ofloxacin content in tears following topical use of 0.3 % ointment. Zhonghua Yan Ke Za Zhi Chin. J. Ophthalmol. 1991; 27 (2): 115–7.</mixed-citation><mixed-citation xml:lang="en">Zhou J.S. Ofloxacin content in tears following topical use of 0.3 % ointment. Zhonghua Yan Ke Za Zhi Chin. J. Ophthalmol. 1991; 27 (2): 115–7.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Егоров А.Е. Офлоксацин 0,3 % глазные капли и мазь в современной терапии воспалительно-инфекционных заболеваний глаз (обзор литературы). РМЖ Клиническая офтальмология. 2012; 13 (3): 114–7.</mixed-citation><mixed-citation xml:lang="en">Egorov A.E. Ofloxacin 0.3 % ophthalmological solution and eye ointment in today treatment of inflammatory and infectious eye diseases. Literary review. RMZh. Klinicheskaya oftal’mlogiya. 2012; 13 (3): 114–7 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Галеева Г.З., Расческов А.Ю. Терапия воспалительных заболеваний передней поверхности и придаточного аппарата глаза у детей в свете современных представлений о множественной лекарственной устойчивости возбудителей. Российский офтальмологический журнал. 2017; 10 (2): 87–90. doi: 10.21516/2072-0076-2017-10-2-87-90</mixed-citation><mixed-citation xml:lang="en">Galeeva G.Z., Rascheskov A.Yu. The therapy of inflammatory diseases of the anterior segment and the adnexa of children in the light of modern ideas on multiple drug resistance of pathogens. Russian ophthalmological journal. 2017; 10 (2): 87–90 (In Russ.). doi: 10.21516/2072-0076-2017-10-2-87-90</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Инструкция по медицинскому применению лекарственного препарата Ципромед, капли для глаз 0,3 % (Сентисс Фарма Пвт.Лтд, РУ П N012981/01). Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=620d64ae-fc62-439b-b0d94dd161df0bfc (accessed: 02.12.2024)</mixed-citation><mixed-citation xml:lang="en">Product monograph Cipromed, eye drops 0.3 %. (Sentiss Pharma, Registration code: П N012981/01 (In Russ.). Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=620d64ae-fc62-439b-b0d94dd161df0bfc (accessed: 02.12.2024)</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Инструкция по медицинскому применению лекарственного препарата Офтоципро® (АО «Татхимфармпрепараты», РУ ЛП-№(001649)-(РГ-RU)). Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=eb894369-959f-4d6a-9ec5e7b223152893 (accessed: 02.12.2024)</mixed-citation><mixed-citation xml:lang="en">Product monograph Oftocipro. (JSC «Tatchempharmpreparaty», Registration code: ЛП-№(001649)-(РГ-RU) (In Russ.). Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=eb894369-959f-4d6a-9ec5e7b223152893 (accessed: 02.12.2024)</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Петров С.Ю., Сафонова Д.М. Консерванты в офтальмологических препаратах: от бензалкония хлорида к поликватернию. РМЖ Клиническая офтальмология. 2014; 14 (2): 97–108.</mixed-citation><mixed-citation xml:lang="en">Petrov S.Yu., Safonova D.M. Ophthalmic preservatives: from benzalkonium chloride to polyquaternium. Literature review. RMZh. Klinicheskaya oftal’mlogiya. 2014; 14 (2): 97–108. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Закирова Г.З., Расческов А.Ю. Глазная мазь Офтоципро в комплексном лечении кератитов у детей. Российский офтальмологический журнал. 2015; 8 (4): 38–41.</mixed-citation><mixed-citation xml:lang="en">Galeeva G.Z., Rascheskov A.Yu. Oftocipro eye ointment in the combined treatment of keratitis in children. Russian ophthalmological journal. 2015; 8 (4): 38–41 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Goldstein MH, Silva FQ, Blender N, Tran T, Vantipalli S. Ocular benzalkonium chloride exposure: problems and solutions. Eye (Lond). 2022 Feb; 36 (2): 361–8. doi: 10.1038/s41433-021-01668-x</mixed-citation><mixed-citation xml:lang="en">Goldstein MH, Silva FQ, Blender N, Tran T, Vantipalli S. Ocular benzalkonium chloride exposure: problems and solutions. Eye (Lond). 2022 Feb; 36 (2): 361–8. doi: 10.1038/s41433-021-01668-x</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Azari AA, Arabi A. Conjunctivitis: A systematic review. J Ophthalmic Vis Res. 2020; 15 (3): 372–95. doi: 10.18502/jovr.v15i3.7456</mixed-citation><mixed-citation xml:lang="en">Azari AA, Arabi A. Conjunctivitis: A systematic review. J Ophthalmic Vis Res. 2020; 15 (3): 372–95. doi: 10.18502/jovr.v15i3.7456</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Трубилин В.Н. Терапевтическая офтальмология и заболевания г лазной поверхности: Учебное пособие. Москва: ФМБА, 2023.</mixed-citation><mixed-citation xml:lang="en">Trubilin V.N. Therapeutic ophthalmology and diseases of the ocular surface: A textbook. Moscow: FMBA, 2023 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Drago L. Topical antibiotic therapy in the ocular environment: The benefits of using Moxifloxacin eyedrops: 4. Microorganisms. Multidisciplinary Digital Publishing Institute. 2024; 12 (4): 649. doi: 10.3390/microorganisms12040649</mixed-citation><mixed-citation xml:lang="en">Drago L. Topical antibiotic therapy in the ocular environment: The benefits of using Moxifloxacin eyedrops: 4. Microorganisms. Multidisciplinary Digital Publishing Institute. 2024; 12 (4): 649. doi: 10.3390/microorganisms12040649</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Oikonomakou M-Z, Makri OE, Panoutsou E, et al. Bacteriology and antimicrobial susceptibility patterns of childhood acute bacterial conjunctivitis in Western Greece. Med. Hypothesis Discov. Innov. Ophthalmol. J. 2019; 8 (4): 266–71. PMID: 31788487</mixed-citation><mixed-citation xml:lang="en">Oikonomakou M-Z, Makri OE, Panoutsou E, et al. Bacteriology and antimicrobial susceptibility patterns of childhood acute bacterial conjunctivitis in Western Greece. Med. Hypothesis Discov. Innov. Ophthalmol. J. 2019; 8 (4): 266–71. PMID: 31788487</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Khor W-B, Lakshminarayanan R, Periayah MH, et al. The antibiotic resistance profiles of Pseudomonas aeruginosa in the Asia Cornea Society Infectious Keratitis Study. Int Ophthalmol. 2024; 44 (1): 361. doi: 10.1007/s10792-024-03270-y</mixed-citation><mixed-citation xml:lang="en">Khor W-B, Lakshminarayanan R, Periayah MH, et al. The antibiotic resistance profiles of Pseudomonas aeruginosa in the Asia Cornea Society Infectious Keratitis Study. Int Ophthalmol. 2024; 44 (1): 361. doi: 10.1007/s10792-024-03270-y</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Chatterjee S, Agrawal D, Gomase SN, et al. Fluoroquinolone resistance in bacterial isolates from ocular infections: Trend in antibiotic susceptibility patterns between 2005-2020. Indian J. Ophthalmol. 2022; 70 (12): 4391–8. doi: 10.4103/ijo.IJO_1033_22</mixed-citation><mixed-citation xml:lang="en">Chatterjee S, Agrawal D, Gomase SN, et al. Fluoroquinolone resistance in bacterial isolates from ocular infections: Trend in antibiotic susceptibility patterns between 2005-2020. Indian J. Ophthalmol. 2022; 70 (12): 4391–8. doi: 10.4103/ijo.IJO_1033_22</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Cabrera-Aguas M, Chidi-Egboka N, Kandel H, Watson SL. Antimicrobial resistance in ocular infection: A review. Clin Exp Ophthalmol. 2024 Apr; 52 (3): 258–5. doi: 10.1111/ceo.14377</mixed-citation><mixed-citation xml:lang="en">Cabrera-Aguas M, Chidi-Egboka N, Kandel H, Watson SL. Antimicrobial resistance in ocular infection: A review. Clin Exp Ophthalmol. 2024 Apr; 52 (3): 258–5. doi: 10.1111/ceo.14377</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Lomholt JA, Kilian M. Ciprofloxacin susceptibility of Pseudomonas aeruginosa isolates from keratitis. Br J Ophthalmol. 2003; 87 ( 10): 1238–40. doi: 10.1136/bjo.87.10.1238</mixed-citation><mixed-citation xml:lang="en">Lomholt JA, Kilian M. Ciprofloxacin susceptibility of Pseudomonas aeruginosa isolates from keratitis. Br J Ophthalmol. 2003; 87 ( 10): 1238–40. doi: 10.1136/bjo.87.10.1238</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Aramă V. Topical antibiotic therapy in eye infections — myths and certainties in the era of bacterial resistance to antibiotics. Romanian J Ophthalmol. 2020; 64 (3): 245–60.</mixed-citation><mixed-citation xml:lang="en">Aramă V. Topical antibiotic therapy in eye infections — myths and certainties in the era of bacterial resistance to antibiotics. Romanian J Ophthalmol. 2020; 64 (3): 245–60.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Воронцова Т.Н., Попов В.Ю., Шапорова В.Я. Результаты определения минимальной подавляющей концентрации современных местных антибактериальных препаратов. Офтальмология. 2014; 11 (3): 68–73. doi: 10.18008/1816-5095-2014-3-68-73</mixed-citation><mixed-citation xml:lang="en">Vorontsova T.N., Popov V.Y., Shaporova V.J. Minimal inhibitory concentrations of modern topical antimicrobials. Ophthalmology. 2014; 11 (3): 68–73. (In Russ.). doi: 10.18008/1816-5095-2014-3-68-73</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Wilhelmus KR, Hyndiuk RA, Caldwell DR, et al. 0.3 % ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis. The Ciprofloxacin Ointment/Bacterial Keratitis Study Group. Arch. Ophthalmol. 1993; 111 (9): 1210–8. doi: 10.1001/archopht.1993.01090090062020</mixed-citation><mixed-citation xml:lang="en">Wilhelmus KR, Hyndiuk RA, Caldwell DR, et al. 0.3 % ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis. The Ciprofloxacin Ointment/Bacterial Keratitis Study Group. Arch. Ophthalmol. 1993; 111 (9): 1210–8. doi: 10.1001/archopht.1993.01090090062020</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Абдулаева А.Э., Амиров А.Н., Сайфуллина Ф.Р. Применение препарата Офтоципро в лечении инфекционно-воспалительных заболеваний переднего отрезка глаза. Российский офтальмологический журнал. 2013; 6 (2): 101–3.</mixed-citation><mixed-citation xml:lang="en">Abdulaeva A.E., Amiriov A.N., Sajfullina F.R. Using Oftocipro in the treatment of infectious and inflammatory diseases of the anterior segment of the eye. Russian ophthalmological journal, 2013; 6 (2): 101–3 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Трубилин В.Н., Полунина Е.Г., Анджелова Д.В. и др. Применение антибактериальных глазных мазей в лечении острых и хронических заболеваний век и конъюнктивы. Офтальмология. 2019; 16 (1): 31–7. https://doi.org/10.18008/1816-5095-2019-1-31-37</mixed-citation><mixed-citation xml:lang="en">Trubilin V.N., Polunina E.G., Angelova D.V., et al. The antibacterial eye ointments in the treatment of eyelids and conjunctiva acute and chronic diseases. Ophthalmology. 2019; 16 (1): 31–7 (In Russ.). https://doi.org/10.18008/1816-5095-2019-1-31-37</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Трубилин В.Н., Полунина Е.Г., Кожухов А.А. и др. Медикаментозная терапия конъюнктивитов. Литературный обзор. Глаз. 2023; 25 (3): 225–33. https://doi.org/10.33791/2222-4408-2023-3-225-233</mixed-citation><mixed-citation xml:lang="en">Trubilin V.N., Polunina E.G., Kozhukhov A.A., et al. Medical therapy for conjunctivitis. Literature review. The EYE. 2023; 25 (3): 225–33 (In Russ.). https://doi.org/10.33791/2222-4408-2023-3-225-233</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Трубилин В.Н., Полунина Е.Г., Анджелова Д.В. и др. Алгоритм лечения мейбомиита, ячменя и халязиона. Офтальмология. 2019; 16 (4): 515–21. https://doi.org/10.18008/1816-5095-2019-4-515-521</mixed-citation><mixed-citation xml:lang="en">Trubilin V.N., Poluninа E.G., Andzhelova D.V., et al. The treatment algorithm for meibomyitis, hordeolum and halazion. Ophthalmology. 2019; 16 (4): 515–21 (In Russ.). https://doi.org/10.18008/1816-5095-2019-4-515-521</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Рыскулова Э.К., Хуснитдинова Э.Г., Исрафилова Г.З., Бабушкин А.Э. Эффективность мази Офтоципро в лечении бактериальных кератитов и язв роговицы. Точка Зрения Восток — Запад. 2016; 1: 142–4.</mixed-citation><mixed-citation xml:lang="en">Ryskulova E.К., Khusnitdinova E.G., Israfilova G.Z., Babushkin A.E. Ointment Ofticipro efficiency in the treatment of bacterial keratitis and corneal ulcers. Point of View. East – West. 2016; 1: 142–4 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Ефимова Е.Л., Бржеский В.В. Новые возможности антибактериальной терапии блефароконъюнктивита у детей. Офтальмология. 2021; 18 (4): 932–7. https://doi.org/10.18008/1816-5095-2021-4-932-937</mixed-citation><mixed-citation xml:lang="en">Efimova E.L., Brzheskiy V.V. New possibilities of antibiotic therapy for blepharoconjunctivitis in children. Ophthalmology in Russia. 2021; 18 (4): 932–7 (In Russ.). https://doi.org/10.18008/1816-5095-2021-4-932-937</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Kumar N, Kumar R, Malhotra M, et al. Ophthalmic ointment &amp; formulation: A review. Int J Med Pharm Drug Res. 2024; 8 (2): 47–60. doi: 10.22161/ijmpd.8.2.6</mixed-citation><mixed-citation xml:lang="en">Kumar N, Kumar R, Malhotra M, et al. Ophthalmic ointment &amp; formulation: A review. Int J Med Pharm Drug Res. 2024; 8 (2): 47–60. doi: 10.22161/ijmpd.8.2.6</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
